J
Jutta Steinseifer
Researcher at Hoffmann-La Roche
Publications - 15
Citations - 1669
Jutta Steinseifer is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 8, co-authored 11 publications receiving 1465 citations. Previous affiliations of Jutta Steinseifer include Novartis.
Papers
More filters
Journal ArticleDOI
Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer
José Baselga,Vladimir Semiglazov,Peter van Dam,Alexey Manikhas,Meritxell Bellet,Jose I. Mayordomo,Mario Campone,Ernst Kubista,Richard Greil,Giulia Bianchi,Jutta Steinseifer,Betty Molloy,Erika Tokaji,Humphrey Gardner,Penny Phillips,Michael Stumm,Heidi Lane,J Michael Dixon,Walter Jonat,Hope S. Rugo +19 more
TL;DR: Everolimus significantly increased letrozole efficacy in neoadjuvant therapy of patients with ER-positive breast cancer and the safety profile was consistent with historical results of everolimus monotherapy.
Journal ArticleDOI
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
Luca Gianni,Wolfgang Eiermann,Vladimir Semiglazov,Ana Lluch,Sergei Tjulandin,Milvia Zambetti,Angela Moliterni,Federico Vazquez,Mikhail Byakhov,Mikhail Lichinitser,Miguel Angel Climent,Eva Ciruelos,Belén Ojeda,Mauro Mansutti,Bozhok Aa,Domenico Magazzu,Dominik Heinzmann,Jutta Steinseifer,Pinuccia Valagussa,José Baselga +19 more
TL;DR: These results show a sustained benefit in event-free survival from trastuzumab-containing neoadjuvant therapy followed by adjuvant trastzumab in patients with locally advanced or inflammatory breast cancer, and provide new insight into the association between pathological complete remission and long-term outcomes in HER2-positive disease.
Journal ArticleDOI
Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01)
Evandro de Azambuja,Marion Procter,Dirk J. van Veldhuisen,Dominique Agbor-Tarh,Otto Metzger-Filho,Jutta Steinseifer,Michael Untch,Ian E. Smith,Luca Gianni,José Baselga,Christian Jackisch,David Cameron,Richard Bell,Brian Leyland-Jones,Mitch Dowsett,Richard D. Gelber,Martine Piccart-Gebhart,Thomas M. Suter +17 more
TL;DR: Long-term assessment at 8-year median follow-up confirms the low incidence of cardiac events for trastuzumab given sequentially after chemotherapy and radiotherapy, and cardiac events were reversible in the vast majority of patients.
Journal ArticleDOI
The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics.
Ahmad Awada,Fatima Cardoso,Christel Fontaine,Luc Dirix,Jacques De Greve,Christos Sotiriou,Jutta Steinseifer,Carine Wouters,Chiaki Tanaka,Ulrike Zoellner,Pui Tang,Martine Piccart +11 more
TL;DR: Daily therapy with RAD001 plus letrozole is promising: the results suggest anti-tumour activity with no PK interactions, and the overall safety profile of the combination is consistent with that expected for RAD001 monotherapy.
Journal ArticleDOI
Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer.
Matthew J. Ellis,Li Lin,Robert J. Crowder,Yu Tao,Jeremy Hoog,Jacqueline E. Snider,Sherri R. Davies,Katherine DeSchryver,Dean B. Evans,Jutta Steinseifer,Raj Bandaru,Weihua Liu,Humphrey Gardner,Vladimir Semiglazov,Mark A. Watson,Kelly K. Hunt,John A. Olson,José Baselga +17 more
TL;DR: PIK3CA mutation status did not strongly interact with neoadjuvant endocrine therapy responsiveness in estrogen receptor-positive breast cancer, and the mechanism for the favorable prognostic impact of PIK3 CA mutation status remains unexplained.